RNLX / Renalytix: Commercializing First AI Kidney Disease Diagnostic Tool

Renalytix AI PLC Sponsored ADR (RNLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings pros more_horizontal

Renalytix PLC (AIM:RENX) shares fell 12% to 46.09p after it said newly allowed US patents further strengthen the core intellectual property underpi more_horizontal

Renalytix AI PLC Sponsored ADR (RNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with st more_horizontal

Shares of Renalytix PLC (AIM:RENX) surged 28% in early trading after the Centers for Medicare & Medicaid Services (CMS) announced a price of $950 for more_horizontal

Renalytix Plc (NASDAQ:RNLX ) Q4 2023 Earnings Conference Call September 28, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners Jame more_horizontal

Renalytix PLC (AIM:RENX) shares ramped 7.5% higher to 128.95p on Friday morning after it announced a distribution agreement for its kidneyintelX.dkd more_horizontal

Renalytix's lead product, KidneyIntelX, an AI diagnostic tool for kidney disease, has received FDA approval and established insurance reimbursement, p more_horizontal

Renalytix (NASDAQ: RNLX ) stock is rising higher on Friday after the medical company got marketing permission from the FDA. According to a press relea more_horizontal